The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1707
July 22, 2024
View Complete Issue         Table of Contents 2019 
Iloperidone (Fanapt) — A New Indication for Bipolar Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iloperidone (Fanapt) — A New Indication for Bipolar Disorder
July 22, 2024 (Issue: 1707)
The oral second-generation antipsychotic drug iloperidone (Fanapt – Vanda) has been approved by the FDA for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. First approved in 2009 for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iloperidone (Fanapt) — A New Indication for Bipolar Disorder
Article code: 1707c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.